Kinavet CA-1 moves forward to trials

Kinavet CA-1 drew FDA ire last month for bogus marketing claims, with the regulator slamming down on its French drugmaker, AB Science, for boasting off-label uses without seeking approval. The regulator went as far as to say the "evidence that Kinavet is an unapproved new animal drug is particularly compelling" in its warning letter. But the canine cancer drug, intended to treat mast cell tumors, has gone ahead to a Phase III clinical trial in Florida. Article

Suggested Articles

The United Nations’ 2030 Agenda for Sustainable Development lays out a host of priorities including “food security and nutrition,” an ambitious plan to…

VetStem Biopharma has treated more than 12,000 companion animals with stem cells removed from their own bodies and then reinjected to treat a variety of joint…

Miami-based biotech Opko Health is branching out into animal health, joining one of the fastest growing segments of the industry: oncology. But the company--…